Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
暂无分享,去创建一个
[1] D. Medaglini,et al. Correlates of vaccine-induced protective immunity against Ebola virus disease. , 2018, Seminars in immunology.
[2] T. Monath,et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. , 2018, The Lancet. Infectious diseases.
[3] A. Schuchat,et al. The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV[INCREMENT]G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak , 2018, The Journal of infectious diseases.
[4] T. Monath,et al. Phase 2 Placebo‐Controlled Trial of Two Vaccines to Prevent Ebola in Liberia , 2017, The New England journal of medicine.
[5] M. Kieny,et al. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial , 2017, PLoS medicine.
[6] Rodolphe Thiébaut,et al. Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV , 2017, Cell Reports.
[7] W. J. Ramsey,et al. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. , 2017, The Lancet. Infectious diseases.
[8] W. J. Ramsey,et al. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial , 2017, Canadian Medical Association Journal.
[9] H. Feldmann,et al. Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection , 2017, Scientific Reports.
[10] T. Monath,et al. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa , 2017, Science Translational Medicine.
[11] M. Addo,et al. Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization☆ , 2017, EBioMedicine.
[12] G. Kobinger,et al. The ongoing evolution of antibody-based treatments for Ebola virus infection. , 2017, Immunotherapy.
[13] G. Mattiuzzo,et al. Comparison of platform technologies for assaying antibody to Ebola virus , 2017, Vaccine.
[14] John-Arne Røttingen,et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) , 2017, The Lancet.
[15] W. J. Ramsey,et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine , 2017, The New England journal of medicine.
[16] R. Davey,et al. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies , 2016, Nature Medicine.
[17] Michael A Proschan,et al. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. , 2016, The New England journal of medicine.
[18] Desmond E. Williams,et al. Prevention of sexual transmission of Ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of Ebola virus RNA results and behavioural data. , 2016, The Lancet. Global health.
[19] G. Wilkie,et al. Late Ebola virus relapse causing meningoencephalitis: a case report , 2016, The Lancet.
[20] Jason A. Regules,et al. Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine , 2016, Scientific Reports.
[21] M. Altfeld,et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. , 2016, The New England journal of medicine.
[22] S. Plotkin. Zika as still another argument for a new path to vaccine development , 2016, Clinical Microbiology and Infection.
[23] F. Spertini,et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. , 2016, The Lancet. Infectious diseases.
[24] James D. Campbell,et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial , 2016, The Lancet. Infectious diseases.
[25] S. Yerly,et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. , 2015, The Lancet. Infectious diseases.
[26] Edward Wright,et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. , 2015, The New England journal of medicine.
[27] M. Katze,et al. Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates , 2013, Proceedings of the National Academy of Sciences.
[28] Majidat A. Muhammad,et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease , 2012, Proceedings of the National Academy of Sciences.
[29] K. Mansfield,et al. Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates , 2012, PLoS neglected tropical diseases.
[30] H. Feldmann,et al. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. , 2011, The Journal of infectious diseases.
[31] X. Qiu,et al. Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses , 2009, PloS one.
[32] N. Sullivan,et al. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule , 2009, Nature Reviews Microbiology.
[33] Heinz Feldmann,et al. Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus , 2009, Journal of Virology.
[34] Steven J M Jones,et al. Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates , 2008, PLoS pathogens.
[35] L. Fernando,et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. , 2007, The Journal of infectious diseases.
[36] N. Sullivan,et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.
[37] H. Feldmann,et al. Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses , 2004, Journal of Virology.
[38] N. Sullivan,et al. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule , 2009, Nature Reviews Microbiology.